Business Wire

GA-CYBLE

6.8.2024 11:03:28 CEST | Business Wire | Press release

Share
Cyble Appoints Ernest Fung as Chief Financial Officer to Drive Financial Strategy and Global Expansion

Cyble, a global leader in AI-powered Gen 3 Cyber Threat Intelligence and digital risk protection, is excited to announce the appointment of Ernest Fung as its new Chief Financial Officer (CFO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802353537/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cyble Appoints Ernest Fung as Chief Financial Officer (Photo: Business Wire)

With a rich background in corporate finance and investment strategies, Ernest brings invaluable expertise and leadership to Cyble. His role will be instrumental in enhancing the company’s financial strategy and driving its global expansion.

Ernest’s distinguished career spans over two decades across several sectors. He previously served as Chief Investment Officer at GoTo Group, Indonesia’s largest technology company. where he led GoTo’s $1 billion IPO, and secured over $1.3 billion in funding in GoTo’s pre-IPO financing. Ernest also served as Chief Investment Officer at Tokopedia, the leading e-commerce company in Indonesia, where he led the $18 billion merger with Gojek to form GoTo Group. Prior to his leadership positions at GoTo and Tokopedia, Ernest led International Corporate Development at JD.com, one of the largest e-commerce companies in China, and was a Director of Technology Investment Banking at Citigroup.

Beenu Arora, CEO of Cyble, stated, “We are delighted to welcome Ernest to our executive team. His understanding of financial strategy for managing high-growth companies will be invaluable as we scale our operations globally.”

Manish Chachada, COO of Cyble, added, “Ernest’s expertise in financial management and his strategic vision will be crucial as we expand our product offerings.”

"I am excited to join Cyble, one of the most innovative cybersecurity companies in the world," said Ernest. "I look forward to working closely with the Cyble team to achieve the company’s vision."

Cyble has recently received significant accolades, including being named an Innovation Leader in the Frost Radar™: Cyber Threat Intelligence 2024 by Frost & Sullivan. The company was also recognized in three Gartner Hype Cycle™ reports for the DRPS category, featured in Forrester's ASM Landscape 2024 report, and highlighted as a leader in G2’s Dark Web Monitoring Providers grid.

About Cyble

Cyble, the world's fastest-growing Gen 3 cyber threat intelligence company, offers comprehensive coverage across adversaries, infrastructure, exposures, weaknesses, and targets. Leveraging AI and ML, Cyble provides critical intelligence to help governments and enterprises protect citizens and infrastructure. Headquartered in Atlanta, Georgia, Cyble also has offices in Australia, Malaysia, Singapore, Dubai, Saudi Arabia, and India.

To learn more visit http://www.cyble.com/request-demo

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240802353537/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye